ClinicalTrials.gg
CompletedNCT04618211RAPIDe-1Updated Dec 17, 2025Results posted

Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema

A Phase 2 interventional study of Deucrictibant and Placebo in Hereditary Angioedema, Hereditary Angioedema Type I and Hereditary Angioedema Type II, sponsored by Pharvaris Netherlands B.V.. Completed at 36 sites in 13 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-17.

Sponsored by Pharvaris Netherlands B.V. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 84 studies in Angioedemas, Hereditary with a site in United States — 12 open to participants now, 18 under way, 10 of them phase 3. Angioedemas, Hereditary · United States.

Enrollment
35th of 74
74 · median 57
Started
2021
with 4 others
Phase 2
16 of 84
1 open now
Registered
47th of 84
by date
Lead sponsor
7 of 84
Pharvaris Netherlands B.V.

Among the 84 studies in Angioedemas, Hereditary with a site in United States, this one is the 35th largest by enrollment of the 74 interventional ones that give a count, is one of 5 that started in 2021, is one of 16 in phase 2, and was the 47th registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

12 of the 84 studies in Angioedemas, Hereditary with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in Angioedemas, Hereditary with a site in United States, or all of them as a file.
02

Study summary

This study evaluates the efficacy of orally administered deucrictibant for the acute treatment of attacks in patients with hereditary angioedema (HAE). Eligible subjects are randomized to one of three single doses of deucrictibant and placebo. The study will compare symptom relief (skin pain, skin swelling, abdominal pain) during HAE attacks and safety of each dose of deucrictibant with placebo.

Read the detailed description

In Part I of the study, patients in non-attack state receive the assigned active single dose of deucrictibant at the study center to assess pharmacokinetics (the way the body absorbs, distributes, and gets rid of the drug) and safety. In Part II of the study, patients self-administer blinded study drug at home to treat three HAE attacks with deucrictibant or placebo (cross-over).

03

Conditions studied

  • Hereditary Angioedema
  • Hereditary Angioedema Type I
  • Hereditary Angioedema Type II
  • Hereditary Angioedema Types I and II
  • Hereditary Angioedema Attack
  • Hereditary Angioedema With C1 Esterase Inhibitor Deficiency
  • Hereditary Angioedema - Type 1
  • Hereditary Angioedema - Type 2
  • C1 Esterase Inhibitor Deficiency
  • C1 Inhibitor Deficiency

Keywords

  • HAE
  • HAE Type I
  • HAE Type II
  • Oral Treatment
  • Bradykinin B2 Receptor Antagonists
  • PHVS416
  • PHA121
  • PHA-022121
  • Deucrictibant
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Signed and dated form
  2. Diagnosis of HAE type I or II
  3. Documented history of HAE attacks: at least three in the last 4 months, or at least two in the last 2 months prior to screening
  4. Reliable access and experience to use standard of care acute attack medications

Key Exclusion Criteria:

  1. Pregnancy or breast-feeding
  2. abnormal
  3. Any other systemic disease or significant disease or disorder that would interfere with the patient's safety or ability to participate in the study
  4. Use of C1-esterase inhibitor, oral kallikrein inhibitors, attenuated androgens, anti-fibrinolytics, or monoclonal HAE therapy within a defined period prior to enrollment
  5. Positive serology for or active infection with virus or virus
  6. Abnormal hepatic function
  7. Abnormal renal function
  8. History of alcohol or drug abuse within defined period, or current evidence of substance dependence or abuse
  9. History of documented severe to any medicinal product
  10. Participation in any other drug study within defined period
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
74 participants (actual)

Study arms

  • Other
    Low dose/placebo

    Single low dose of deucrictibant or placebo

    Drug: Deucrictibant · Drug: Placebo

  • Other
    Medium dose/placebo

    Single medium dose of deucrictibant or placebo

    Drug: Deucrictibant · Drug: Placebo

  • Other
    High dose/placebo

    Single high dose of deucrictibant or placebo

    Drug: Deucrictibant · Drug: Placebo

Interventions

  • DrugDeucrictibant

    deucrictibant soft capsules for oral use

    Also known as: PHA-022121, PHA121, PHVS416

  • DrugPlacebo

    Matching placebo capsules for oral use

06

What researchers measure

Primary outcomes

  1. Change of the 3-symptom Composite Visual Analogue Scale (VAS-3) Score From Pre-treatment to 4 Hours Post-treatment

    The primary endpoint of the study was the change of the VAS-3 (3-symptom composite visual analogue scale) score from pre-treatment to 4 hours post-treatment. The VAS-3 was calculated as the mean of the VAS scores of the 3 major HAE symptoms: skin swelling, skin pain, and abdominal pain. The VAS scores of the 3 major HAE symptoms (skin swelling, skin pain, and abdominal pain) could range between 0 (No swelling/No pain) and 100 (Extreme swelling/Excruciating pain)

    Time frame: Assessed from pre-treatment to 4 hours post-treatment

Secondary outcomes

  1. Time to Onset of Symptom Relief by ≥30% Reduction in Visual Analogue Scale (VAS-3) Composite Score From the Pre-treatment Score

    VAS-3 scores range between 0 and 100.

    Time frame: Assessed from pre-treatment to 48-hours post-treatment

  2. Time to Onset of Almost Complete or Complete Symptom Relief by Visual Analogue Scale (VAS-3)

    VAS scores range between 0 and 100. Almost complete symptom relief is defined as all 3 individual VAS scores of the VAS-3 having a value \< 10. Complete symptom relief is defined as all 3 individual VAS scores are of the VAS-3 having a value of 0.

    Time frame: Assessed from pre-treatment to 48 hours post-treatment

  3. Time to a ≥50% Reduction in VAS-3 Composite Score From the Pre-treatment Score

    Time to a ≥50% reduction in VAS-3 composite score from the pre-treatment score.

    Time frame: Assessed from pre-treatment to 48 hours post-treatment

  4. Change in the Mean Symptom Complex Severity (MSCS) Score From Pre-treatment to 4 Hours Post-treatment

    MSCS scores range between 0 and 3. A higher score means a worse outcome.

    Time frame: Pre-treatment and 4 hours post-treatment

  5. Treatment Outcome Score (TOS) at 4 Hours Post-treatment

    TOS range between -100 and 100. A positive score indicates improvement, a score of 0 indicates no change, and a negative score indicates worsening compared to pre-treatment.

    Time frame: 4 hours post-treatment

  6. Time to Onset of Primary Symptom Relief Assessed by a 30% Reduction in the VAS for the Primary Symptom

    Time to onset of primary symptom relief assessed by a 30% reduction in the VAS for the primary symptom within 48 hours post-treatment

    Time frame: Within 48 hours post-treatment

  7. Proportion of Study Drug Treated Attacks Requiring HAE Rescue Medication Within 12 Hours.

    Proportion of blinded study drug treated attacks requiring HAE rescue medication within 12 hours post-treatment.

    Time frame: Assessed at 12 hours post study drug treatment

  8. Time to First HAE Rescue Medication Use for Study Drug-treated Attacks Within 48 Hours Post-treatment

    The proportion of treated attacks with first use of HAE rescue medication within 48 hours post-treatment with PHA-022121.

    Time frame: Assessed at 48 hours post study drug treatment

  9. Time to Change in the VAS Score for Skin Pain Score - 30% Reduction

    Time to change in the VAS score for Skin Pain Score - 30% reduction within 48-hours post-treatment. VAS-3 scores range between 0 and 100. A larger reduction means a better outcome.

    Time frame: Within 48 hours post treatment

  10. Change in Mean Symptom Complex Severity Score From Pre-treatment to 24 Hours Post-treatment

    Change in the Mean Symptom Complex Severity (MSCS) score from pre-treatment to 24 hours post-treatment. A lower MSCS score indicates a better outcome.

    Time frame: 24 hours post-treatment

  11. TOS at 24 Hours Post-treatment

    Treatment outcome score at 24 hours post-treatment. A higher score indicates improvement.

    Time frame: Assessed within 24 hours post treatment

  12. Treatment Satisfaction Questionnaire for Medication Scores at 48 Hours Post-treatment - Effectiveness Domain Score

    MMRM analysis of Treatment Satisfaction Questionnaire for Medication (TSQM) at 48 hours post-treatment. The 11-item TSQM (version II) evaluated participant treatment satisfaction with the medication for the following scales: effectiveness, side effects, convenience, and overall satisfaction Scale scores were transformed into scores ranging from 0 to 100 and could be used to calculate a total composite score, a higher score indicating greater satisfaction.

    Time frame: 48 hours post-treatment

  13. Time to Onset of Primary Symptom Relief by 50% Reduction in VAS Score

    Time to Onset of Primary Symptom Relief by 50% Reduction in VAS Score within 48 hours post-treatment. VAS-3 scores range between 0 and 100. A larger reduction means a better outcome.

    Time frame: Within 48 hours post-treatment

  14. Proportion of Study Drug Treated Attacks Requiring HAE Rescue Medication Within 24 Hours.

    Qualifying attacks treated with study drug may use approved rescue medication if no symptom relief within 4 hours has been experienced.

    Time frame: Assessed at 24 hours post-study drug treatment

  15. Proportion of Study Drug Treated Attacks Requiring HAE Rescue Medication Within 48 Hours

    Qualifying attacks treated with study drug may use approved rescue medication if no symptom relief within 4 hours has been experienced.

    Time frame: Assessed at 48 hours post-study drug treatment

  16. Treatment Satisfaction Questionnaire for Medication Scores at 48 Hours Post-treatment - Convenience Domain Score

    MMRM analysis of Treatment Satisfaction Questionnaire for Medication (TSQM) at 48 hours post-treatment. The 11-item TSQM (version II) evaluated participant treatment satisfaction with the medication for the following scales: effectiveness, side effects, convenience, and overall satisfaction Scale scores were transformed into scores ranging from 0 to 100 and could be used to calculate a total composite score, a higher score indicating greater satisfaction.

    Time frame: 48 hours post-treatment

  17. Treatment Satisfaction Questionnaire for Medication Scores at 48 Hours Post-treatment - Satisfaction Domain Score

    MMRM analysis of Treatment Satisfaction Questionnaire for Medication (TSQM) at 48 hours post-treatment. The 11-item TSQM (version II) evaluated participant treatment satisfaction with the medication for the following scales: effectiveness, side effects, convenience, and overall satisfaction Scale scores were transformed into scores ranging from 0 to 100 and could be used to calculate a total composite score, a higher score indicating greater satisfaction.

    Time frame: 48 hours post-treatment

  18. Time to Change in the VAS Score for Skin Swelling Score - 30% Reduction

    Time to change in the VAS score for Skin Swelling Score - 30% reduction within 48 hours post-treatment. VAS-3 scores range between 0 and 100. A larger reduction means a better outcome.

    Time frame: Within 48 hours post-treatment

  19. Time to Change in the VAS Score for Abdominal Pain Score - 30% Reduction

    Time to change in the VAS score for Abdominal Pain Score - 30% reduction within 48 hours post-treatment. VAS-3 scores range between 0 and 100. A larger reduction means a better outcome.

    Time frame: Within 48 hours post-treatment

07

Results

Posted Dec 17, 2025
Limitations and caveats
Primary analysis is presented. For the endpoints "Time to Onset of Symptom Relief by 30% Reduction in Visual Analogue Scale (VAS-3)," "Time to almost or complete symptom relief by VAS," \& "Time to 50% reduction in VAS-3," the within participant correlation was not accounted for in the Kaplan-Meier estimation of median time and corresponding 95% confidence interval. Participant flow is reported according to randomized treatment cohort, efficacy \& safety results are according to treatment group.

Participant flow

A total of 89 patients were screened, of which 74 patients were enrolled and randomized to the 3 PHA-022121 cohorts as follows: 25 participants to the 30 mg cohort, 25 participants to the 20 mg cohort, and 24 participants to the 10 mg cohort. From Part I to Part II, participants remained at their randomly assigned dose level. The majority of screen failures were due to inclusion criterion not met.

Part I (Non-Attack, Safety)
Participant flow — Part I (Non-Attack, Safety)
MilestonePHA-022121 Low Dose - 10 mgPHA-022121 Medium Dose - 20 mgPHA-022121 High Dose - 30 mg
Started242525
Completed242425
Not completed010
Withdrew: Withdrawal by subject010
Part II (Self-administration, Efficacy)
Participant flow — Part II (Self-administration, Efficacy)
MilestonePHA-022121 Low Dose - 10 mgPHA-022121 Medium Dose - 20 mgPHA-022121 High Dose - 30 mg
Started242425
Attack 1 - pha-022121161317
Attack 1 - placebo666
Attack 2 - pha-02212112812
Attack 2 - placebo787
Attack 3 - pha-022121111010
Attack 3 - placebo736
Completed161212
Not completed81213
Withdrew: Withdrawal by subject235
Withdrew: Participants met primary analysis criteria698

Outcome measures

PrimaryChange of the 3-symptom Composite Visual Analogue Scale (VAS-3) Score From Pre-treatment to 4 Hours Post-treatment

The primary endpoint of the study was the change of the VAS-3 (3-symptom composite visual analogue scale) score from pre-treatment to 4 hours post-treatment. The VAS-3 was calculated as the mean of the VAS scores of the 3 major HAE symptoms: skin swelling, skin pain, and abdominal pain. The VAS scores of the 3 major HAE symptoms (skin swelling, skin pain, and abdominal pain) could range between 0 (No swelling/No pain) and 100 (Extreme swelling/Excruciating pain)

Time frame:
Assessed from pre-treatment to 4 hours post-treatment
Reported as:
Least squares mean · Score on a scale
Change of the 3-symptom Composite Visual Analogue Scale (VAS-3) Score From Pre-treatment to 4 Hours Post-treatment
Score on a scalePHA-022121 Low Dose - 10 mgPHA-022121 Medium Dose - 20 mgPHA-022121 High Dose - 30 mgPlacebo
Change of the 3-symptom Composite Visual Analogue Scale (VAS-3) Score From Pre-treatment to 4 Hours Post-treatment-14.83 ± 1.833-13.10 ± 2.111-14.37 ± 1.9751.92 ± 1.596
Statistical analysis
  • PHA-022121 Low Dose - 10 mg vs Placebo · Mixed model repeated measures · p = < 0.0001 (Nominal p-value) · Least squares mean difference: -16.75 · 95% CI -21.52 to -11.97
  • PHA-022121 Medium Dose - 20 mg vs Placebo · Mixed model repeated measures · p = < 0.0001 · Least squares mean difference: -15.02 · 95% CI -20.22 to -9.81
  • PHA-022121 High Dose - 30 mg vs Placebo · Mixed model repeated measures · p = < 0.0001 · Least squares mean difference: -16.28 · 95% CI -21.27 to -11.29
SecondaryTime to Onset of Symptom Relief by ≥30% Reduction in Visual Analogue Scale (VAS-3) Composite Score From the Pre-treatment Score

VAS-3 scores range between 0 and 100.

Time frame:
Assessed from pre-treatment to 48-hours post-treatment
Reported as:
Median · Hours
Time to Onset of Symptom Relief by ≥30% Reduction in Visual Analogue Scale (VAS-3) Composite Score From the Pre-treatment Score
HoursPHA-022121 Low Dose -10 mgPHA-022121 Medium Dose - 20 mgPHA-022121 High Dose - 30 mgPlacebo
Time to Onset of Symptom Relief by ≥30% Reduction in Visual Analogue Scale (VAS-3) Composite Score From the Pre-treatment Score2.1 (1.5 to 2.9)2.7 (1.9 to 3.5)2.5 (1.9 to 3.8)8.0 (7.6 to 48.0)
Statistical analysis
  • PHA-022121 Low Dose -10 mg · Marginal Cox Proportional Hazards Model · p = < 0.0001 (Nominal p-value) · Hazard ratio (hr): 3.81 · 95% CI 2.01 to 7.2
  • PHA-022121 Medium Dose - 20 mg · Marginal Cox Proportional Hazards Model · p = 0.0021 · Hazard ratio (hr): 3.08 · 95% CI 1.5 to 6.3
  • PHA-022121 High Dose - 30 mg · Marginal Cox Proportional Hazards Model · p = < 0.0001 · Hazard ratio (hr): 3.61 · 95% CI 2.1 to 6.19
SecondaryTime to Onset of Almost Complete or Complete Symptom Relief by Visual Analogue Scale (VAS-3)

VAS scores range between 0 and 100. Almost complete symptom relief is defined as all 3 individual VAS scores of the VAS-3 having a value \< 10. Complete symptom relief is defined as all 3 individual VAS scores are of the VAS-3 having a value of 0.

Time frame:
Assessed from pre-treatment to 48 hours post-treatment
Reported as:
Median · Hours
Time to Onset of Almost Complete or Complete Symptom Relief by Visual Analogue Scale (VAS-3)
HoursPHA-022121 Low Dose - 10 mgPHA-022121 Medium Dose - 20 mgPHA-022121 High Dose - 30 mgPlacebo
Time to Onset of Almost Complete or Complete Symptom Relief by Visual Analogue Scale (VAS-3)5.8 (3.6 to 7.5)20.0 (4.5 to 20.0)20.0 (6.0 to 20.1)42.0 (22.0 to 48.0)
Statistical analysis
  • PHA-022121 Low Dose - 10 mg vs Placebo · Cox Proportional Hazards Model · p = < 0.0001 (Nominal p-value) · Hazard ratio (hr): 5.09 · 95% CI 2.81 to 9.22
  • PHA-022121 Medium Dose - 20 mg vs Placebo · Marginal Cox Proportional Hazards Model · p = 0.0127 · Hazard ratio (hr): 2.25 · 95% CI 1.19 to 4.27
  • PHA-022121 High Dose - 30 mg vs Placebo · Marginal Cox Proportional Hazards Model · p = 0.0001 · Hazard ratio (hr): 2.65 · 95% CI 1.61 to 4.38
SecondaryTime to a ≥50% Reduction in VAS-3 Composite Score From the Pre-treatment Score

Time to a ≥50% reduction in VAS-3 composite score from the pre-treatment score.

Time frame:
Assessed from pre-treatment to 48 hours post-treatment
Reported as:
Median · Hours
Time to a ≥50% Reduction in VAS-3 Composite Score From the Pre-treatment Score
HoursPHA-022121 Low Dose - 10 mgPHA-022121 Medium Dose - 20 mgPHA-022121 High Dose - 30 mgPlacebo
Time to a ≥50% Reduction in VAS-3 Composite Score From the Pre-treatment Score3.3 (2.4 to 3.9)4.0 (2.9 to 6.0)4.0 (3.3 to 5.8)22.8 (20.0 to 24.1)
Statistical analysis
  • PHA-022121 Low Dose - 10 mg vs Placebo · Marginal Cox Proportional Hazards Model · p = < 0.0001 (Nominal p-value) · Hazard ratio (hr): 4.55 · 95% CI 2.41 to 8.59
  • PHA-022121 Medium Dose - 20 mg vs Placebo · Marginal Cox Proportional Hazards Model · p = 0.0003 · Hazard ratio (hr): 3.65 · 95% CI 1.8 to 7.38
  • PHA-022121 High Dose - 30 mg vs Placebo · Marginal Cox Proportional Hazards Model · p = < 0.0001 · Hazard ratio (hr): 3.87 · 95% CI 2.26 to 6.63
SecondaryChange in the Mean Symptom Complex Severity (MSCS) Score From Pre-treatment to 4 Hours Post-treatment

MSCS scores range between 0 and 3. A higher score means a worse outcome.

Time frame:
Pre-treatment and 4 hours post-treatment
Reported as:
Least squares mean · Score on a scale
Change in the Mean Symptom Complex Severity (MSCS) Score From Pre-treatment to 4 Hours Post-treatment
Score on a scalePHA-022121 Low Dose - 10 mgPHA-022121 Medium Dose - 20 mgPHA-022121 High Dose - 30 mgPlacebo
Change in the Mean Symptom Complex Severity (MSCS) Score From Pre-treatment to 4 Hours Post-treatment-1.08 (-1.33 to -0.83)-0.91 (-1.19 to -0.62)-0.68 (-0.95 to -0.40)-0.29 (-0.51 to -0.08)
Statistical analysis
  • PHA-022121 Low Dose - 10 mg vs Placebo · Mixed model repeated measures · p = < 0.0001 (Nominal p-value) · Least squares mean difference: -0.79 · 95% CI -1.11 to -0.46
  • PHA-022121 Medium Dose - 20 mg vs Placebo · Mixed model repeated measures · p = 0.0008 · Least squares mean difference: -0.61 · 95% CI -0.97 to -0.26
  • PHA-022121 High Dose - 30 mg vs Placebo · Mixed model repeated measures · p = 0.0291 · Least squares mean difference: -0.39 · 95% CI -0.73 to -0.04
SecondaryTreatment Outcome Score (TOS) at 4 Hours Post-treatment

TOS range between -100 and 100. A positive score indicates improvement, a score of 0 indicates no change, and a negative score indicates worsening compared to pre-treatment.

Time frame:
4 hours post-treatment
Reported as:
Least squares mean · Score on a scale
Treatment Outcome Score (TOS) at 4 Hours Post-treatment
Score on a scalePHA-022121 Low Dose - 10 mgPHA-022121 Medium Dose - 20 mgPHA-022121 High Dose - 30 mgPlacebo
Treatment Outcome Score (TOS) at 4 Hours Post-treatment60.52 (41.74 to 79.29)59.08 (37.58 to 80.57)67.44 (47.15 to 87.74)-3.62 (-19.68 to 12.45)
Statistical analysis
  • PHA-022121 Low Dose - 10 mg vs Placebo · Mixed model repeated measures · p = < 0.0001 (Nominal p-value) · Least squares mean difference: 64.13 · 95% CI 40.35 to 87.91
  • PHA-022121 Medium Dose - 20 mg vs Placebo · Mixed model repeated measures · p = < 0.0001 · Least squares mean difference: 62.69 · 95% CI 36.71 to 88.67
  • PHA-022121 High Dose - 30 mg vs Placebo · Mixed model repeated measures · p = < 0.0001 · Least squares mean difference: 71.06 · 95% CI 46.09 to 96.03
SecondaryTime to Onset of Primary Symptom Relief Assessed by a 30% Reduction in the VAS for the Primary Symptom

Time to onset of primary symptom relief assessed by a 30% reduction in the VAS for the primary symptom within 48 hours post-treatment

Time frame:
Within 48 hours post-treatment
Reported as:
Median · Hours
Time to Onset of Primary Symptom Relief Assessed by a 30% Reduction in the VAS for the Primary Symptom
HoursPHA-022121 Low Dose - 10 mgPHA-022121 Medium Dose - 20 mgPHA-022121 High Dose - 30 mgPlacebo
Time to Onset of Primary Symptom Relief Assessed by a 30% Reduction in the VAS for the Primary Symptom2.0 (1.4 to 2.4)3.0 (1.9 to 4.1)2.9 (1.9 to 3.9)23.3 (6.1 to NA)
SecondaryProportion of Study Drug Treated Attacks Requiring HAE Rescue Medication Within 12 Hours.

Proportion of blinded study drug treated attacks requiring HAE rescue medication within 12 hours post-treatment.

Time frame:
Assessed at 12 hours post study drug treatment
Reported as:
Number · Attacks requiring HAE rescue medication
Proportion of Study Drug Treated Attacks Requiring HAE Rescue Medication Within 12 Hours.
Attacks requiring HAE rescue medicationPHA-022121 Low Dose - 10 mgPHA-022121 Medium Dose - 20 mgPHA-022121 High Dose - 30 mgPlacebo
Proportion of Study Drug Treated Attacks Requiring HAE Rescue Medication Within 12 Hours.73231
SecondaryTime to First HAE Rescue Medication Use for Study Drug-treated Attacks Within 48 Hours Post-treatment

The proportion of treated attacks with first use of HAE rescue medication within 48 hours post-treatment with PHA-022121.

Time frame:
Assessed at 48 hours post study drug treatment
Reported as:
Median · Hours
Time to First HAE Rescue Medication Use for Study Drug-treated Attacks Within 48 Hours Post-treatment
HoursPHA-022121 Low Dose - 10 mgPHA-022121 Medium Dose - 20 mgPHA-022121 High Dose - 30 mgPlacebo
Time to First HAE Rescue Medication Use for Study Drug-treated Attacks Within 48 Hours Post-treatmentNA (NA to NA)NA (NA to NA)NA (NA to NA)6.0 (4.4 to 13.1)
SecondaryTime to Change in the VAS Score for Skin Pain Score - 30% Reduction

Time to change in the VAS score for Skin Pain Score - 30% reduction within 48-hours post-treatment. VAS-3 scores range between 0 and 100. A larger reduction means a better outcome.

Time frame:
Within 48 hours post treatment
Reported as:
Median · Hours
Time to Change in the VAS Score for Skin Pain Score - 30% Reduction
HoursPHA-022121 Low Dose - 10 mgPHA-022121 Medium Dose - 20 mgPHA-022121 High Dose - 30 mgPlacebo
Time to Change in the VAS Score for Skin Pain Score - 30% Reduction2.9 (1.9 to 5.7)3.4 (1.9 to 6.0)2.7 (1.9 to 3.9)22.8 (8.7 to NA)
SecondaryChange in Mean Symptom Complex Severity Score From Pre-treatment to 24 Hours Post-treatment

Change in the Mean Symptom Complex Severity (MSCS) score from pre-treatment to 24 hours post-treatment. A lower MSCS score indicates a better outcome.

Time frame:
24 hours post-treatment
Reported as:
Least squares mean · Score on a scale
Change in Mean Symptom Complex Severity Score From Pre-treatment to 24 Hours Post-treatment
Score on a scalePHA-022121 Low Dose - 10 mgPHA-022121 Medium Dose - 20 mgPHA-022121 High Dose - 30 mgPlacebo
Change in Mean Symptom Complex Severity Score From Pre-treatment to 24 Hours Post-treatment-1.65 ± 0.117-1.50 ± 0.123-1.68 ± 0.122-1.20 ± 0.163
SecondaryTOS at 24 Hours Post-treatment

Treatment outcome score at 24 hours post-treatment. A higher score indicates improvement.

Time frame:
Assessed within 24 hours post treatment
Reported as:
Mean · Score on a scale
TOS at 24 Hours Post-treatment
Score on a scalePHA-022121 Low Dose - 10 mgPHA-022121 Medium Dose - 20 mgPHA-022121 High Dose - 30 mgPlacebo
TOS at 24 Hours Post-treatment94.44 ± 21.18393.60 ± 21.19094.44 ± 16.01376.92 ± 38.813
SecondaryTreatment Satisfaction Questionnaire for Medication Scores at 48 Hours Post-treatment - Effectiveness Domain Score

MMRM analysis of Treatment Satisfaction Questionnaire for Medication (TSQM) at 48 hours post-treatment. The 11-item TSQM (version II) evaluated participant treatment satisfaction with the medication for the following scales: effectiveness, side effects, convenience, and overall satisfaction Scale scores were transformed into scores ranging from 0 to 100 and could be used to calculate a total composite score, a higher score indicating greater satisfaction.

Time frame:
48 hours post-treatment
Reported as:
Mean · Score on a scale
Treatment Satisfaction Questionnaire for Medication Scores at 48 Hours Post-treatment - Effectiveness Domain Score
Score on a scalePHA-022121 Low Dose - 10 mgPHA-022121 Medium Dose - 20 mgPHA-022121 High Dose - 30 mgPlacebo
Treatment Satisfaction Questionnaire for Medication Scores at 48 Hours Post-treatment - Effectiveness Domain Score79.17 ± 23.17970.45 ± 30.29072.92 ± 23.08565.38 ± 23.532
SecondaryTime to Onset of Primary Symptom Relief by 50% Reduction in VAS Score

Time to Onset of Primary Symptom Relief by 50% Reduction in VAS Score within 48 hours post-treatment. VAS-3 scores range between 0 and 100. A larger reduction means a better outcome.

Time frame:
Within 48 hours post-treatment
Reported as:
Median · Hours
Time to Onset of Primary Symptom Relief by 50% Reduction in VAS Score
HoursPHA-022121 Low Dose - 10 mgPHA-022121 Medium Dose - 20 mgPHA-022121 High Dose - 30 mgPlacebo
Time to Onset of Primary Symptom Relief by 50% Reduction in VAS Score2.9 (2.4 to 3.9)4.5 (2.9 to 8.5)4.0 (2.5 to 5.8)22.8 (5.8 to 24.1)
SecondaryProportion of Study Drug Treated Attacks Requiring HAE Rescue Medication Within 24 Hours.

Qualifying attacks treated with study drug may use approved rescue medication if no symptom relief within 4 hours has been experienced.

Time frame:
Assessed at 24 hours post-study drug treatment
Reported as:
Number · Attacks requiring HAE rescue medication
Proportion of Study Drug Treated Attacks Requiring HAE Rescue Medication Within 24 Hours.
Attacks requiring HAE rescue medicationPHA-022121 Low Dose - 10 mgPHA-022121 Medium Dose - 20 mgPHA-022121 High Dose - 30 mgPlacebo
Number of treated attacks37283151
Number of treated attacks requiring HAE rescue medication93437
SecondaryProportion of Study Drug Treated Attacks Requiring HAE Rescue Medication Within 48 Hours

Qualifying attacks treated with study drug may use approved rescue medication if no symptom relief within 4 hours has been experienced.

Time frame:
Assessed at 48 hours post-study drug treatment
Reported as:
Number · Attacks requiring HAE rescue medication
Proportion of Study Drug Treated Attacks Requiring HAE Rescue Medication Within 48 Hours
Attacks requiring HAE rescue medicationPHA-022121 Low Dose - 10 mgPHA-022121 Medium Dose - 20 mgPHA-022121 High Dose - 30 mgPlacebo
Number of treated attacks37283151
Number of treated attacks requiring HAE rescue medication94537
SecondaryTreatment Satisfaction Questionnaire for Medication Scores at 48 Hours Post-treatment - Convenience Domain Score

MMRM analysis of Treatment Satisfaction Questionnaire for Medication (TSQM) at 48 hours post-treatment. The 11-item TSQM (version II) evaluated participant treatment satisfaction with the medication for the following scales: effectiveness, side effects, convenience, and overall satisfaction Scale scores were transformed into scores ranging from 0 to 100 and could be used to calculate a total composite score, a higher score indicating greater satisfaction.

Time frame:
48 hours post-treatment
Reported as:
Mean · Score on a scale
Treatment Satisfaction Questionnaire for Medication Scores at 48 Hours Post-treatment - Convenience Domain Score
Score on a scalePHA-022121 Low Dose - 10 mgPHA-022121 Medium Dose - 20 mgPHA-022121 High Dose - 30 mgPlacebo
Treatment Satisfaction Questionnaire for Medication Scores at 48 Hours Post-treatment - Convenience Domain Score80.56 ± 16.56983.08 ± 23.09677.55 ± 20.22976.07 ± 27.441
SecondaryTreatment Satisfaction Questionnaire for Medication Scores at 48 Hours Post-treatment - Satisfaction Domain Score

MMRM analysis of Treatment Satisfaction Questionnaire for Medication (TSQM) at 48 hours post-treatment. The 11-item TSQM (version II) evaluated participant treatment satisfaction with the medication for the following scales: effectiveness, side effects, convenience, and overall satisfaction Scale scores were transformed into scores ranging from 0 to 100 and could be used to calculate a total composite score, a higher score indicating greater satisfaction.

Time frame:
48 hours post-treatment
Reported as:
Mean · Score on a scale
Treatment Satisfaction Questionnaire for Medication Scores at 48 Hours Post-treatment - Satisfaction Domain Score
Score on a scalePHA-022121 Low Dose - 10 mgPHA-022121 Medium Dose - 20 mgPHA-022121 High Dose - 30 mgPlacebo
Treatment Satisfaction Questionnaire for Medication Scores at 48 Hours Post-treatment - Satisfaction Domain Score82.50 ± 18.90780.68 ± 29.70276.74 ± 22.11364.10 ± 24.623
SecondaryTime to Change in the VAS Score for Skin Swelling Score - 30% Reduction

Time to change in the VAS score for Skin Swelling Score - 30% reduction within 48 hours post-treatment. VAS-3 scores range between 0 and 100. A larger reduction means a better outcome.

Time frame:
Within 48 hours post-treatment
Reported as:
Median · Hours
Time to Change in the VAS Score for Skin Swelling Score - 30% Reduction
HoursPHA-022121 Low Dose - 10 mgPHA-022121 Medium Dose - 20 mgPHA-022121 High Dose - 30 mgPlacebo
Time to Change in the VAS Score for Skin Swelling Score - 30% Reduction2.5 (1.4 to 5.8)3.5 (2.2 to 20.0)3.8 (1.9 to 4.8)23.3 (3.9 to NA)
SecondaryTime to Change in the VAS Score for Abdominal Pain Score - 30% Reduction

Time to change in the VAS score for Abdominal Pain Score - 30% reduction within 48 hours post-treatment. VAS-3 scores range between 0 and 100. A larger reduction means a better outcome.

Time frame:
Within 48 hours post-treatment
Reported as:
Median · Hours
Time to Change in the VAS Score for Abdominal Pain Score - 30% Reduction
HoursPHA-022121 Low Dose - 10 mgPHA-022121 Medium Dose - 20 mgPHA-022121 High Dose - 30 mgPlacebo
Time to Change in the VAS Score for Abdominal Pain Score - 30% Reduction1.9 (1.1 to 2.1)1.4 (0.9 to 2.5)2.9 (1.9 to 7.5)20.0 (2.9 to NA)

Adverse events

Collected over All AEs (including SAEs) recorded from the time of signing informed consent until the end-of-study visit. Timeframe for reporting adverse events: 5 days post-treatment.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part I PHA-022121 Low Dose - 10 mg0/23 (0%)0/23 (0%)2/23 (8.7%)
Part I PHA-022121 Medium Dose - 20 mg0/24 (0%)0/24 (0%)2/24 (8.3%)
Part I PHA-022121 High Dose - 30 mg0/25 (0%)0/25 (0%)4/25 (16%)
Part II PHA-022121 Low Dose - 10 mg Study Drug Treated Attacks0/38 (0%)0/38 (0%)3/38 (7.9%)
Part II PHA-022121 Medium Dose - 20 mg Study Drug Treated Attacks0/29 (0%)0/29 (0%)1/29 (3.4%)
Part II PHA-022121 High Dose - 30 mg Study Drug Treated Attacks0/36 (0%)0/36 (0%)2/36 (5.6%)
Part II PHA-022121 Low Dose - 10 mg Participants0/21 (0%)0/21 (0%)3/21 (14.3%)
Part II PHA-022121 Medium Dose - 20 mg Participants0/16 (0%)0/16 (0%)1/16 (6.3%)
Part II PHA-022121 High Dose - 30 mg Participants0/22 (0%)0/22 (0%)2/22 (9.1%)
Part II Placebo0/53 (0%)0/53 (0%)4/53 (7.5%)
Most frequent other events
Showing 10 of 15
Most frequent other events
EventPart I PHA-022121 Low Dose - 10 mgPart I PHA-022121 Medium Dose - 20 mgPart I PHA-022121 High Dose - 30 mgPart II PHA-022121 Low Dose - 10 mg Study Drug Treated AttacksPart II PHA-022121 Medium Dose - 20 mg Study Drug Treated AttacksPart II PHA-022121 High Dose - 30 mg Study Drug Treated AttacksPart II PHA-022121 Low Dose - 10 mg ParticipantsPart II PHA-022121 Medium Dose - 20 mg ParticipantsPart II PHA-022121 High Dose - 30 mg ParticipantsPart II Placebo
HeadacheNervous system disorders0/231/242/250/380/290/360/210/160/220/53
NasopharyngitisInfections and infestations0/230/242/251/380/290/361/210/160/220/53
Lower urinary tract symptomsRenal and urinary disorders0/230/240/250/381/290/360/211/160/220/53
FatigueGeneral disorders0/230/240/251/380/291/361/210/161/220/53
Gastrointestinal infectionInfections and infestations0/230/240/251/380/290/361/210/160/220/53
Blood bilirubin increasedInvestigations0/230/240/250/380/291/360/210/161/220/53
NauseaGastrointestinal disorders1/230/240/250/380/291/360/210/161/220/53
VomitingGastrointestinal disorders0/230/240/250/380/291/360/210/161/220/53
Viral InfectionInfections and infestations1/230/240/250/380/290/360/210/160/220/53
Dental cariesGastrointestinal disorders0/231/240/250/380/290/360/210/160/220/53

Baseline characteristics

Full Analysis Set (FAS): The FAS was defined as all participants enrolled and randomized in the study. Participants were analyzed based on the intention-to-treat principle, i.e., according to their randomized treatment assignment regardless of actual treatment taken.

Age, Continuous
Age, Continuous(years)PHA-022121 Low Dose - 10 mgPHA-022121 Medium Dose - 20 mgPHA-022121 High Dose - 30 mgTotal
Mean42.9 ± 14.1545.7 ± 13.8941.4 ± 15.3843.3 ± 14.41
Age, Customized
Age, Customized(Participants)PHA-022121 Low Dose - 10 mgPHA-022121 Medium Dose - 20 mgPHA-022121 High Dose - 30 mgTotal
Adults (18-64 years)22242369
From 65-84 years2125
Sex: Female, Male
Sex: Female, Male(Participants)PHA-022121 Low Dose - 10 mgPHA-022121 Medium Dose - 20 mgPHA-022121 High Dose - 30 mgTotal
Female17171549
Male781025
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PHA-022121 Low Dose - 10 mgPHA-022121 Medium Dose - 20 mgPHA-022121 High Dose - 30 mgTotal
White22242571
American Indian or Alaska Native1001
Asian1001
Black or African American0000
Other0101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PHA-022121 Low Dose - 10 mgPHA-022121 Medium Dose - 20 mgPHA-022121 High Dose - 30 mgTotal
Hispanic or Latino3205
Not Hispanic or Latino18222464
Not Reported3115
08

Study locations

36 sites
  • Study site
    Birmingham, Alabama 35209, United States
  • Study site
    Paradise Valley, Arizona 85253, United States
  • Study site
    San Diego, California 92122, United States
  • Study site
    Santa Monica, California 90404, United States
  • Study site
    Walnut Creek, California 94598, United States
  • Study site
    Chevy Chase, Maryland 20815, United States
  • Study site
    St Louis, Missouri 63141, United States
  • Study site
    Hershey, Pennsylvania 17033, United States
  • Study site
    Sofia, Bulgaria
  • Study site
    Edmonton, Alberta, Canada
  • Study site
    Ottawa, Ontario, Canada
  • Study site
    Toronto, Ontario, Canada
  • Study site
    Montreal, Quebec, Canada
  • Study site
    Québec, Quebec, Canada
  • Study site
    Brno, Czechia
  • Study site
    Hradec Králové, Czechia
  • Study site
    Grenoble, France
  • Study site
    Montpellier, France
  • Study site
    Paris, France
  • Study site
    Berlin, Germany
  • Study site
    Dresden, Germany
  • Study site
    Frankfurt, Germany
  • Study site
    Mainz, Germany
  • Study site
    Ulm, Germany
  • Study site
    Budapest, Hungary
  • Study site
    Ashkelon, Israel
  • Study site
    Haifa, Israel
  • Study site
    Tel Aviv, Israel
  • Study site
    Monserrato, Italy
  • Study site
    Naples, Italy
  • Study site
    Amsterdam, Netherlands
  • Study site
    Krakow, Poland
  • Study site
    Barcelona, Spain
  • Study site
    Madrid, Spain
  • Study site
    Brighton, United Kingdom
  • Study site
    London, United Kingdom
09

References and documents

Publications

  • Maurer M, Stobiecki M, Valerieva A, Hakl R, Staevska MT, Bouillet L, Du-Thanh A, Kessel A, Kiani-Alikhan S, Magerl M, Reshef A, Baeza ML, Fain O, Farkas H, Greve J, Guilarte M, Jacobs JS, Li HH, Lleonart R, Manning ME, Sussman GL, Anderson J, Chapdelaine H, Cohn DM, Hagin D, Kralickova P, Ritchie B, Spadaro G, Staubach P, Tarzi MD, Yang WH, Jouvin MH, Crabbe R, van Leeuwen S, Chen H, Zhu L, Knolle J, Lesage A, Lu P, Riedl MA, Aygoren-Pursun E. Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Haematol. 2026 Apr;13(4):e200-e214. doi: 10.1016/S2352-3026(25)00341-2. Epub 2026 Mar 19. PubMed 41865747 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Sep 2022, 19 months.

Results were first posted in Dec 2025, 3 years 2 months after primary completion. A results delay was requested in Jun 2023.

Of 17 phase 2 interventional studies under Angioedemas, Hereditary, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's 19 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2020
First posted
Nov 5, 2020
StartActual
Feb 3, 2021
Primary completionActual
Sep 23, 2022
CompletionActual
Mar 1, 2023
Results delay requested
Jun 15, 2023
Results first posted
Dec 17, 2025
Last update
Dec 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04618211
Lead sponsor
Pharvaris Netherlands B.V.
Responsible party
Sponsor
First posted
Nov 5, 2020
Start date
Feb 3, 2021
Primary completion
Sep 23, 2022
Completion
Mar 1, 2023
Results posted
Dec 17, 2025
Last update
Dec 17, 2025

Study contacts

Marcus Maurer, Prof MD
principal investigator · Charite University, Berlin, Germany

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion